MedTrace Logo

Metronomic Gemcitabine, Mitomycin C, and Thalidomide for Advanced Solid Tumors

NCT07671534 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2026-06-26

No results posted yet for this study

Summary

This is an open label phase II study using metronomic low-dose gemcitabine and mitomycin c given intravenously, and thalidomide administered orally, for patients with advanced solid tumors.

Conditions

  • Solid Tumor Cancer

Interventions

DRUG

Gemcitabine

600 mg/m2 (Max: 1000 mg) i.v. on D1, D8, D15

DRUG

Mitomycin C

Mitomycin C 14 mg i.v. every 6 weeks

DRUG

Thalidomide

Thalidomide 100 mg daily x 15 days

Sponsors & Collaborators

  • Sarcoma Oncology Research Center, LLC

    lead OTHER

Principal Investigators

  • Neal S. Chawla, MD · Sarcoma Oncology Research Center, LLC

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-06-30
Primary Completion
2029-06-30
Completion
2029-06-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07671534 on ClinicalTrials.gov